Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: A systematic review and meta-analysis.
Charles E GaberJyotirmoy SarkerAbdullah I AbdelazizEbere OkparaTodd A LeeSamuel J KlempnerRyan David NippPublished in: Cancer medicine (2024)
Under one-third of patients with esophageal cancer who receive neoadjuvant chemo(radiation) experience pCR. Patients diagnosed with squamous cell carcinomas had higher rates of pCR than those with adenocarcinomas. As pCR represents an increasingly utilized endpoint in neoadjuvant trials, these estimates of pooled pCR rates may serve as an important benchmark for future trial design.
Keyphrases
- locally advanced
- neoadjuvant chemotherapy
- rectal cancer
- squamous cell carcinoma
- squamous cell
- lymph node
- radiation therapy
- end stage renal disease
- real time pcr
- ejection fraction
- chronic kidney disease
- phase iii
- newly diagnosed
- study protocol
- prognostic factors
- clinical trial
- peritoneal dialysis
- randomized controlled trial
- drug delivery
- current status
- patient reported
- open label
- early stage